Skip to Main Content

Author Details

Aline Talhouk
The University of British Columbia
2015
64
27
PMIDPaper TitleJournal TitlePublished Year
36029832Reoperation and pain-related outcomes after hysterectomy for endometriosis by oophorectomy status.Am J Obstet Gynecol2023
37321155Harmonized molecular classification; assessment of a single-test ProMisE NGS tool.Gynecol Oncol2023
36948887p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study.J Pathol Clin Res2023
37182372Corrigendum to "Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death": [Modern Pathology 36 (2023) 100085].Mod Pathol2023
37339172The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas.Clin Cancer Res2023
36790339Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma.Cancer Epidemiol Biomarkers Prev2023
36753816Molecular subtype stratified outcomes according to adjuvant therapy in endometrial cancer.Gynecol Oncol2023
36788084Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death.Mod Pathol2023
36572991CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.Cancer2023
36735436Symptom and Anatomical Phenotypes Provide Insights Into Interactions of Prolapse Symptoms and Anatomy.Urogynecology (Phila)2023
36731023Targeted Molecular Testing in Endometrial Carcinoma: Validation of a Clinically Driven Selective ProMisE Testing Protocol.Int J Gynecol Pathol2023
36368129Profiling the immune landscape in mucinous ovarian carcinoma.Gynecol Oncol2023
34782936MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma.Virchows Arch2022
35768582Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression.NPJ Precis Oncol2022
35860688Wearable Biosensors in the Workplace: Perceptions and Perspectives.Front Digit Health2022
35866380Spatial expression of the FGFR2b splice isoform and its prognostic significance in endometrioid endometrial carcinoma.J Pathol Clin Res2022
36222710Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes.Clin Cancer Res2022
35877228Gynecologic Cancer Risk and Genetics: Informing an Ideal Model of Gynecologic Cancer Prevention.Curr Oncol2022
35246332Variation in practice in endometrial cancer and potential for improved care and equity through molecular classification.Gynecol Oncol2022
35138400Outcomes From Opportunistic Salpingectomy for Ovarian Cancer Prevention.JAMA Netw Open2022
34897700Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8<sup>+</sup> TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas.J Pathol2022
33469880Somatic Genomic Events in Endometriosis: Review of the Literature and Approach to Phenotyping.Reprod Sci2021
33793971Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis.Cancer2021
34863191From biobank and data silos into a data commons: convergence to support translational medicine.J Transl Med2021
34662288Correction: Person-Generated Health Data in Women's Health: Protocol for a Scoping Review.JMIR Res Protoc2021
34314024Reply to Survival analysis and treatment effects in patients with endometrial cancer and POLE mutations.Cancer2021
34047708Person-Generated Health Data in Women's Health: Protocol for a Scoping Review.JMIR Res Protoc2021
32414751FGFR2c Mesenchymal Isoform Expression Is Associated with Poor Prognosis and Further Refines Risk Stratification within Endometrial Cancer Molecular Subtypes.Clin Cancer Res2020
31954537Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.Gynecol Oncol2020
31768620DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics.J Cancer Res Clin Oncol2020
32686118Synthesis of diagnostic quality cancer pathology images by generative adversarial networks.J Pathol2020
32737030Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma.Clin Cancer Res2020
32555365Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium.Br J Cancer2020
32554541Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).Clin Cancer Res2020
32360491Proteomic analysis of transitional cell carcinoma-like variant of tubo-ovarian high-grade serous carcinoma.Hum Pathol2020
32473302Prognostic gene expression signature for high-grade serous ovarian cancer.Ann Oncol2020
30326146Nuclear β-catenin and CDX2 expression in ovarian endometrioid carcinoma identify patients with favourable outcome.Histopathology2019
30059451Tubo-Ovarian Transitional Cell Carcinoma and High-grade Serous Carcinoma Show Subtly Different Immunohistochemistry Profiles.Int J Gynecol Pathol2019
31239549A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases.Mod Pathol2019
30922603Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma.Gynecol Oncol2019
30821698Causes of death among women with epithelial ovarian cancer by length of survival post-diagnosis: a population-based study in British Columbia, Canada.Int J Gynecol Cancer2019
30523022Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma.Clin Cancer Res2019
29334888diceR: an R package for class discovery using an ensemble driven approach.BMC Bioinformatics2018
30050154L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile.Br J Cancer2018
30062862Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study.J Pathol Clin Res2018
30359249Long-term mortality among women with epithelial ovarian cancer: a population-based study in British Columbia, Canada.BMC Cancer2018
29432521Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series.Ann Oncol2018
28061006Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.Cancer2017
28257152Human papillomavirus (HPV)-independent vulvar squamous cell carcinoma has a worse prognosis than HPV-associated disease: a retrospective cohort study.Histopathology2017
28079598Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup.Am J Surg Pathol2017
  • 1 - 50 of 64

Recommended Authors

Arnaud Da Cruz Paula
Memorial Sloan Kettering Cancer Center
Career Start Year 2018
Number of shared co-authors 4
Pier Selenica
Memorial Sloan Kettering Cancer Center
Career Start Year 2017
Number of shared co-authors 6
Arnaud Da Cruz Paula
Memorial Sloan Kettering Cancer Center
Career Start Year 2014
Number of shared co-authors 3
Padma S Rajagopal
National Cancer Institute, National Institutes of Health
Career Start Year 2014
Number of shared co-authors 0
Cathleen Matrai
Weill Cornell Medical Center
Career Start Year 2013
Number of shared co-authors 0
Nicholas C Spies
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year 2013
Number of shared co-authors 2
Amanda L Strickland
Northwestern University Feinberg School of Medicine
Career Start Year 2013
Number of shared co-authors 0
Ekaterina Olkhov-Mitsel
University of Toronto
Career Start Year 2012
Number of shared co-authors 0
Yuexin Liu
The University of Texas MD Anderson Cancer Center
Career Start Year 2011
Number of shared co-authors 6
Ghassan Allo
Henry Ford Hospital
Career Start Year 2011
Number of shared co-authors 13
Eloise Chapman-Davis
Weill Cornell Medical College
Career Start Year 2009
Number of shared co-authors 0
Darragh G McArt
Queen's University Belfast
Career Start Year 2009
Number of shared co-authors 0
Myriam Kossai
INSERM, Universite Clermont Auvergne
Career Start Year 2008
Number of shared co-authors 1
Divya Gupta
Emory University School of Medicine
Career Start Year 2006
Number of shared co-authors 2
Christina Yau
University of California San Francisco
Career Start Year 2005
Number of shared co-authors 8
Donal J Brennan
National Centre for Peritoneal Malignancy, Mater Misericordiae University Hospital
Career Start Year 2005
Number of shared co-authors 24
Markus Riester
Novartis Institutes for BioMedical Research
Career Start Year 2005
Number of shared co-authors 2
Leah M Prentice
British Columbia Women's Hospital and Health Centre
Career Start Year 2004
Number of shared co-authors 44
Katherine A Hoadley
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Career Start Year 2004
Number of shared co-authors 11
Andrew H Beck
Beth Israel Deaconess Medical Center, Harvard Medical School
Career Start Year 2004
Number of shared co-authors 19
Jennifer B Permuth
Moffitt Cancer Center
Career Start Year 2004
Number of shared co-authors 75
Britta Weigelt
Memorial Sloan Kettering Cancer Center
Career Start Year 2002
Number of shared co-authors 29
Richard B Schwab
Department of Medicine and Moores Cancer Center, University of California San Diego
Career Start Year 2000
Number of shared co-authors 0
Susan C Modesitt
University of Virginia, Emily Couric Clinical Cancer Center
Career Start Year 1998
Number of shared co-authors 3
Ingrid Hedenfalk
Lund University and Skane University Hospital
Career Start Year 1997
Number of shared co-authors 4
Kevin Holcomb
Weill Cornell Medical College
Career Start Year 1996
Number of shared co-authors 1
Jan Budczies
Institute of Pathology, University Hospital Heidelberg
Career Start Year 1996
Number of shared co-authors 4
Paulette Mhawech-Fauceglia
University of Southern California
Career Start Year 1995
Number of shared co-authors 10
Fr??d??ric Amant
Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 53
Ronny Drapkin
University of Pennsylvania School of Medicine
Career Start Year 1980
Number of shared co-authors 70

Collaborators

Cyril B Gilks
University of British Columbia
Co-authored papers 37
David G Huntsman
University of British Columbia
Co-authored papers 37
Samuel Leung
University of British Columbia
Co-authored papers 29
Martin K??bel
University of Calgary
Co-authored papers 24
Stefan Kommoss
Eberhard Karls University Tubingen
Co-authored papers 24
Derek S Chiu
University of British Columbia, and Vancouver General Hospital
Co-authored papers 23
Michael S Anglesio
University of British Columbia
Co-authored papers 20
Susan J Ramus
School of Clinical Medicine, University of NSW Sydney, Lowy Cancer Research Centre
Co-authored papers 14
Amy Lum
University of British Columbia
Co-authored papers 13
Anna DeFazio
Westmead Hospital
Co-authored papers 12
Paul D P Pharoah
Center for Cancer Genetic Epidemiology, University of Cambridge
Co-authored papers 12
Ellen L Goode
Mayo Clinic College of Medicine
Co-authored papers 11
Janine Senz
University of British Columbia
Co-authored papers 11
Naveena Singh
Barts Health NHS Trust
Co-authored papers 11
James D Brenton
CRUK Cambridge Institute, University of Cambridge
Co-authored papers 11
Linda E Kelemen
Hollings Cancer Center, Medical University of South Carolina
Co-authored papers 10
Hans-Peter Sinn
Pathologisches Institut, Universitatsklinikum Heidelberg
Co-authored papers 10
David D L Bowtell
Peter MacCallum Cancer Centre
Co-authored papers 10
Catherine J Kennedy
The Westmead Institute for Medical Research, University of Sydney
Co-authored papers 10
Jacek Gronwald
International Hereditary Cancer Center, Pomeranian Medical University
Co-authored papers 10
Simon A Gayther
Cedars-Sinai Medical Center
Co-authored papers 10
Jennifer Alsop
University of Cambridge
Co-authored papers 10
Mercedes Jimenez-Linan
University of Cambridge
Co-authored papers 10
Stacey J Winham
Mayo Clinic
Co-authored papers 9
Aleksandra Gentry-Maharaj
UCL EGA Institute for Women's Health, University College London
Co-authored papers 9
Usha Menon
College of Nursing, University of South Florida
Co-authored papers 9
Sian Fereday
Peter MacCallum Cancer Centre
Co-authored papers 9
Michael E Carney
John A. Burns School of Medicine, University of Hawaii
Co-authored papers 8
Marc T Goodman
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Co-authored papers 8
Helen Steed
University of Alberta, Canada Cross Cancer Institute
Co-authored papers 8
Release 1.2